Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ropivacaine · Naropin

Small molecule · developed by Fresenius Kabi Usa

Approved FDA, Sep 1996

1 Registered trials

What is Ropivacaine?

Ropivacaine is an amide local anesthetic used to produce local or regional anesthesia for surgery, including epidural block for cesarean section, and for acute pain management, such as postoperative or labor pain. It is also being studied in pregnancy-related conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Naropin
Drug type: Small molecule
Therapy area: Women's health
Developer: Fresenius Kabi Usa
In trials of: GRCE
FDA status: Approved as Naropin (September 24, 1996), NDA020533 · FDA label

✅ FDA-approved uses

Surgical anesthesia
Acute pain management

From the indications section of the FDA label (version of Jul 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05487196	Phase 2	Pregnancy Related	Completed	GRCE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pregnancy Related

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z